3NT will use the funds to complete its family of specialty single-use endoscope and therapeutic devices and initiate commercialization of Sinusway platform in the US and Europe, advancing care in ear, nose and throat (ENT) disorders.
The financing round was led by Hoya and it is its first venture investment in an Israeli company.
Hoya joins present investors including LongTec China Ventures and an elite group of angel investors, medical device industry veterans and ENT practitioners who are supporting the company.
3NT CEO Ehud Bendory said: “We are honored to have HOYA join our team of investors. their investment is a strong validation of the team’s efforts to establish single-use endoscopy platforms as the next standard of care in ENT.”
HOYA chief legal officer and corporate development global head Augustine Yee said: “HOYA’s investment in 3NT continues our commitment to partner with innovative medical device companies that align with our core strategic areas of interest.
“We are excited about 3NT’s disruptive visualization technologies, and the benefits their devices will bring to ENT surgeons and their patients.”
3NT stated that traditionally, advances in visualization have pushed the envelope for minimally invasive surgery for ENTs. But, exiting endoscopes can provide only fractional views of peripheral intra-sinus anatomy.
At the same time, surgical instruments are becoming more flexible and reaching further, leaving endoscopes behind.
3NT’s new endoscopy technology allows ENT surgeons to see what’s next, driving treatment into farthest reaches of the anatomy.
Hoya is a Japan-based medical technology company and a supplier of high-tech and medical products.
The company is active in the fields of healthcare and information technology, offering eyeglasses, medical endoscopes, intraocular lenses and optical lenses as well as key components for semiconductor devices, LCD panels and HDDs. It has more than 150 offices and subsidiaries in the world.
